Olmetab
Generic Name
Olmesartan Medoxomil
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmetab 10 mg tablet | ৳ 3.50 | ৳ 35.00 |
| olmetab 20 mg tablet | ৳ 4.50 | ৳ 45.00 |
| olmetab 40 mg tablet | ৳ 7.00 | ৳ 70.00 |
Description
Overview of the medicine
Olmetab contains Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), used to treat high blood pressure (hypertension). It helps to relax blood vessels, allowing blood to flow more easily and thereby lowering blood pressure.
Uses & Indications
Dosage
Adults
The recommended starting dose is 20 mg once daily. The dose can be increased to 40 mg once daily if blood pressure is not adequately controlled. Maximum daily dose is 40 mg.
Elderly
No initial dose adjustment is generally required for elderly patients (≥65 years) unless there is severe renal impairment.
Renal_impairment
In patients with moderate to severe renal impairment (creatinine clearance <40 mL/min), a starting dose of 10 mg once daily is recommended. Close monitoring of blood pressure and renal function is advised.
How to Take
Olmetab tablets can be taken with or without food. It should be swallowed whole with water. Take at the same time each day.
Mechanism of Action
Olmesartan Medoxomil is a prodrug that is rapidly converted to the active compound olmesartan. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in various tissues, including vascular smooth muscle and the adrenal gland. This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
Pharmacokinetics
Onset
Onset of antihypertensive effect within 2 hours; maximal reduction within 8 weeks.
Excretion
Excreted primarily in feces (50-65%) via biliary excretion and approximately 35-50% via urine. Renal clearance is about 0.5-0.7 L/h.
Half life
Approximately 10-15 hours.
Absorption
Rapidly and completely absorbed from the gastrointestinal tract; bioavailability is approximately 26%. Peak plasma concentrations are reached within 1-2 hours.
Metabolism
Olmesartan Medoxomil is completely and rapidly hydrolyzed to olmesartan during absorption from the gastrointestinal tract. No further metabolism of olmesartan occurs.
Side Effects
Contraindications
- Hypersensitivity to Olmesartan Medoxomil or any component of the formulation.
- Pregnancy (second and third trimesters).
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment.
- Severe hepatic impairment, biliary obstruction.
Drug Interactions
NSAIDs
May reduce the antihypertensive effect and increase the risk of renal impairment, especially in elderly or volume-depleted patients.
Lithium
Increases serum lithium concentrations and toxicity. Monitor lithium levels.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes or renal impairment.
Potassium-sparing diuretics/Potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose are likely to be hypotension and possibly tachycardia; bradycardia could occur. Treatment should be symptomatic and supportive. If ingestion is recent, gastric lavage may be considered. Administer intravenous fluids to support blood pressure.
Pregnancy & Lactation
Olmesartan Medoxomil is contraindicated in the second and third trimesters of pregnancy due to risk of fetal injury and death. Use in the first trimester is not recommended. It is not known whether olmesartan is excreted in human milk, but due to potential adverse effects on the nursing infant, it is generally not recommended during lactation.
Side Effects
Contraindications
- Hypersensitivity to Olmesartan Medoxomil or any component of the formulation.
- Pregnancy (second and third trimesters).
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment.
- Severe hepatic impairment, biliary obstruction.
Drug Interactions
NSAIDs
May reduce the antihypertensive effect and increase the risk of renal impairment, especially in elderly or volume-depleted patients.
Lithium
Increases serum lithium concentrations and toxicity. Monitor lithium levels.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes or renal impairment.
Potassium-sparing diuretics/Potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose are likely to be hypotension and possibly tachycardia; bradycardia could occur. Treatment should be symptomatic and supportive. If ingestion is recent, gastric lavage may be considered. Administer intravenous fluids to support blood pressure.
Pregnancy & Lactation
Olmesartan Medoxomil is contraindicated in the second and third trimesters of pregnancy due to risk of fetal injury and death. Use in the first trimester is not recommended. It is not known whether olmesartan is excreted in human milk, but due to potential adverse effects on the nursing infant, it is generally not recommended during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from manufacturing date
Availability
Available in pharmacies nationwide
Approval Status
Approved by FDA/DGDA
Patent Status
Off-patent in many regions
Clinical Trials
Clinical trials have demonstrated Olmesartan's efficacy in lowering blood pressure across various patient populations, including those with comorbidities like type 2 diabetes and renal impairment. Studies also support its safety profile when used as monotherapy or in combination.
Lab Monitoring
- Monitor renal function (serum creatinine, BUN) periodically, especially in patients with pre-existing renal impairment or those on diuretics. Monitor serum potassium levels, especially in patients at risk of hyperkalemia (e.g., elderly, renal impairment, concomitant use with potassium-sparing diuretics).
- Regular blood pressure monitoring.
Doctor Notes
- Advise patients to report any severe diarrhea or unexplained weight loss immediately.
- Monitor serum electrolytes and renal function at baseline and periodically during treatment.
- Educate patients on the importance of adherence to therapy and lifestyle modifications for effective blood pressure control.
Patient Guidelines
- Take Olmetab exactly as prescribed by your doctor, usually once daily.
- Do not stop taking this medicine suddenly without consulting your doctor, even if you feel well, as your blood pressure may increase.
- Inform your doctor about all other medications you are taking, including over-the-counter drugs and herbal supplements.
- Avoid driving or operating machinery if you experience dizziness or lightheadedness, especially at the start of treatment.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
This medicine may cause dizziness or lightheadedness, particularly at the start of treatment or when changing doses. If you experience these effects, avoid driving or operating machinery.
Lifestyle Advice
- Maintain a healthy lifestyle, including a balanced diet low in sodium and saturated fats.
- Engage in regular physical activity as advised by your doctor.
- Limit alcohol consumption.
- Quit smoking to further improve cardiovascular health.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olmetab Brand
Other medicines available under the same brand name
